Discover
ACON
Aclarion, Inc.
3.02
2 x 2.19
2 x 3.68
bid
ask
+
0.14
4.86%
2 @ 04:00 AM
2.93 -0.09 (2.98%)
| Ytd | -34.35% | |
| 1y | -60.32% |
2.88
day range
3.05
2.34
52 week range
12.03
| Open | 2.88 | Prev Close | 2.88 | Low | 2.88 | High | 3.05 | Mkt Cap | 7.44M |
| Vol | 26.15K | Avg Vol | 106.22K | EPS | -5.63 | P/E | N/A | Forward P/E | -0.24 |
| Beta | 0.40 | Short Ratio | 0.77 | Inst. Own | 3.57% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.20 | 200-d Avg | 4.77 | 1yr Est | 1.30 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.18 | -0.15 | 0.03 | 16.67% |
| 2024-08-14 | 2024-06 | 0 | -0.15 | N/A | N/A |
| 2024-08-14 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -0.44 | N/A | N/A |
| 2024-04-02 | 2023-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-13 | Maxim Group | Downgrade | Buy | Hold |
| 2024-11-27 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-08-26 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-07-29 | Ascendiant Capital | Upgrade | Buy |
Profile
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-12-28 | LORBIECKI JOHN PAUL | Chief Financial Officer | 22.40K | Purchase |
| 2022-12-28 | NESS BRENT | Chief Executive Officer | 19.50K | Purchase |
| 2023-02-15 | THRAMANN JEFFREY JOHN | Officer and Director | 1.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Captrust Financial Advisors | 214.03K | 27.40K | 2.05% |
| 2024-09-29 | Two Sigma Securities, LLC | 49.30K | 6.31K | 0.47% |
| 2024-09-29 | UBS Group AG | 39.97K | 5.12K | 0.38% |
| 2024-09-29 | Geode Capital Management, LLC | 33.89K | 4.34K | 0.32% |
| 2024-09-29 | Susquehanna International Group, LLP | 14.15K | 1.81K | 0.14% |
| 2024-09-29 | Jane Street Group, LLC | 12.24K | 1.57K | 0.12% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 33.27K | 4.26K | 0.32% |
Split
| Split | Date |
|---|---|
| 1 : 27 | 2025-03-28 |
| 1 : 335 | 2025-01-30 |
| 1 : 370 | 2025-01-29 |
| 1 : 16 | 2024-01-04 |